Forgetting too much isn’t the only memory problem a person can have. Someone can also forget too little. Bernard Schreurs, a researcher with the WVU School of Medicine and Rockefeller Neuroscience Institute, is exploring the mechanisms behind Alzheimer’s disease and PTSD. What his studies reveal could suggest new ways to prevent and treat these conditions. NIH has awarded the work $6.3 million over five years.

Quantum Catalyzer (Q-Cat), a new company in the heart of Maryland's research corridor and led by University of Maryland's Dr. Ronald Walsworth, is on a mission to create and grow successful quantum technology start-ups.

The National Institute of Neurological Disorders and Stroke has awarded a $4 million grant (UG3 NS119199) as the first portion of what is anticipated to be a $30 million award over six years to the Keck School of Medicine of USC to conduct a pivotal Phase 3 clinical trial of the experimental drug 3K3A-APC. It’s a novel second-generation variant of a naturally occurring human protein. The trial will gauge the efficacy of 3K3A-APC as a cerebroprotectant, a drug that hastens or augments recovery when combined with two standard treatments for acute ischemic stroke. The drug will also be tested as a treatment aimed at minimizing brain bleeds. The remainder of the grant will be funded in subsequent allotments pending review of milestones.

How we speak matters to animals. Horses, pigs and wild horses can distinguish between negative and positive sounds from their fellow species and near relatives, as well as from human speech. This, according to new research in behavioral biology at the University of Copenhagen. The study provides insight into the history of emotional development and opens up interesting perspectives with regards to animal welfare.